Affect of Advertisements on Treatment Compliance in Women With Breast Cancer - Full Text View

Sponsored by:	Institut Bergonie
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00462410

Purpose

RATIONALE: Measuring how advertising affects treatment compliance in women with breast cancer may help doctors plan the best treatment.

PURPOSE: This clinical trial is studying how advertisements affect treatment compliance in women with breast cancer.

Condition	Intervention
Breast Cancer	Procedure: counseling Procedure: psychosocial assessment and care

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Health Services Research, Open Label
Official Title:	Socio-Anthropological Study Evaluating the Impact of Observance or Treatment in Patients With Breast Cancer

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Treatment compliance [ Designated as safety issue: No ]

Secondary Outcome Measures:

Factors affecting adherence to the medical plan [ Designated as safety issue: No ]

Estimated Enrollment:	65
Study Start Date:	March 2006

Detailed Description:

OBJECTIVES:

Primary

Evaluate the consequences of advertisement on treatment compliance in women with breast cancer.

Secondary

Determine the factors favoring or not favoring adherence to the medical recommendations.

OUTLINE: Patients and their medical and nonmedical caregivers are interviewed by a sociologist or anthropologist twice over 1 year. The first interview is at the consultation visit and the second interview is at the patient's home. The impact of advertisement on treatment compliance is measured.

PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study.

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of breast cancer
Hormone receptor status not specified

PATIENT CHARACTERISTICS:

Female
Menopausal status not specified

PRIOR CONCURRENT THERAPY:

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00462410

Sponsors and Collaborators

Institut Bergonie

Investigators

Study Chair:

Marc Debled, MD

Institut Bergonie

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000540528, IB-2006-03, INCA-REF0145, INCA-SOCIO-ANTHROPO
Study First Received:	April 18, 2007
Last Updated:	July 23, 2008
ClinicalTrials.gov Identifier:	NCT00462410
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

recurrent breast cancer
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer

stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Study placed in the following topic categories:

Skin Diseases
Breast Neoplasms
Breast Diseases
Recurrence

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009